In the Original Investigation titled “Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease in the United Kingdom,”[1] published January 10, 2022, there were data errors in the columns displaying results for the total cohort and incidence group under the header “Satukijchai et al” in Table 2 and an error in a 95% CI given in the Abstract for the association between transverse myelitis at onset and risk of relapse. This article has been corrected.[1]
Authors: Chanjira Satukijchai; Romina Mariano; Silvia Messina; Mario Sa; Mark R Woodhall; Neil P Robertson; Lim Ming; Evangeline Wassmer; Rachel Kneen; Saif Huda; Anu Jacob; Camilla Blain; Christopher Halfpenny; Cheryl Hemingway; Eoin O'Sullivan; Jeremy Hobart; Leonora K Fisniku; Roswell Martin; Ruth Dopson; Sarah A Cooper; Victoria Williams; Patrick J Waters; Sithara Ramdas; Maria Isabel Leite; Jacqueline Palace Journal: JAMA Netw Open Date: 2022-01-04